ATM germline pathogenic in mCRPC: olaparib approved per PROfound (Cohort A included ATM);...
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | BMA-ATM-GERMLINE-PROSTATE |
|---|---|
| Type | Actionability |
| Status | reviewed 2026-04-27 | pending_clinical_signoff | actionability review required |
| Diseases | DIS-PROSTATE |
| Sources | SRC-CIVIC SRC-EAU-PROSTATE-2024 SRC-ESMO-PROSTATE-2024 SRC-NCCN-PROSTATE-2025 |
Actionability Facts
| Biomarker | BIO-HRR-PANEL |
|---|---|
| Variant | ATM germline pathogenic |
| Disease | DIS-PROSTATE |
| ESCAT tier | IB |
| Recommended combinations | olaparib monotherapy (post-NHA), talazoparib + enzalutamide (1L, HRR-mut) |
| Evidence summary | ATM germline pathogenic in mCRPC: olaparib approved per PROfound (Cohort A included ATM); benefit smaller than BRCA but FDA/EMA-labeled. Talazoparib+enzalutamide and olaparib+abiraterone also include ATM in HRR- mutated populations. ESCAT IB / OncoKB Level 1. |
Notes
EMA label more restrictive than FDA — restricts olaparib to BRCA1/2 only in EU. Cascade testing mandatory; ATM carriers face elevated breast/pancreatic risk in relatives.
Used By
No reverse references found in the YAML corpus.